Watch video on YouTube here: Facebook Local App
via S&S Pro Channel
Watch video on YouTube here: Facebook Local App
via S&S Pro Channel
Market Insights
The intraoperative neuromonitor has enormous value in medical industry in terms of patient safety. With the changing perspective of medical technology, the adoption of such devices is increasing and assumed to see substantial growth in future. The assessment of neuronal function during surgical intervention is of higher importance to avoid the further complications caused by damage or injury of nervous system. Prevention of permanent damage of neuronal system is vital to circumvent the paralysis, muscle weakness, hearing loss or further serious complications.
Browse the full report Intraoperative Neuromonitoring (IONM) Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at http://www.credenceresearch.com/report/intraoperative-neuromonitoring-market
Increasing prevalence of neurological disorder, rising awareness of patient safety, growing neurological centers are the major drivers of the intraoperative neuromonitoring market. The increasing adoption of technologically advanced procedures, healthcare expenditure for R&D to manufacture newer and innovative technologies, favorable reimbursement policies boost up the growth of intraoperative neuromonitor market. However, the lack of appropriate skilled health professional and lack of awareness in developing countries are few major challenges associated with the intraoperative neuromonitoring market.
The intraoperative neuromonitoring market is segmented on the basis of type of source such as insourced IONM and outsourced IONM. Although the insourced IONM is estimated to dominate the intraoperative neuromonitoring market, but in upcoming years the outsourced IONM is expected to witness major growth.
The intraoperative neuromonitoring market is further classified on the basis of application type and the sub-segments are as follows:
The spinal surgery and neurosurgery hold the major market share and anticipated to face significant growth in forecasting periods driven.
Request Sample: http://www.credenceresearch.com/sample-request/58673
Geographically, in the year 2016, North America is expected to have the major share of intraoperative neuromonitoring market followed by Europe. The well-developed healthcare infrastructure, increasing demand for neurologic care, rising patient safety, presence of major players of intraoperative neuromonitoring devices attribute to the dominance of North American region. The huge number of population suffering from neurologic disorders, emerging medical tourism and developing healthcare infrastructure fuel the growth of the intraoperative neuromonitoring market in Asia-Pacific region and it is expected to face substantial growth in upcoming periods due to the growing trend of health awareness.
Market Competition Assessment:
The intraoperative neuromonitoring market currently contains multiple companies having their products marketed. The manufacturers are developing new innovative products and the market is growing due to high adoption and accessibilities of these products. The companies include Medtronic plc., Computational Diagnostics, Inc., NuVasive, Inc., Inomed Medizintechnik GmbH, Accurate Monitoring LLC, Nihon Kohden Corporation, Moberg Research, Inc. and others.
Key Market Movements:
Ø The rising prevalence of neurological disorder, increasing awareness of patient safety, growing neurological centers, increasing adoption of technologically advanced procedures, healthcare expenditure for R&D to manufacture newer and innovative technologies, favorable reimbursement policies boost up the growth of intraoperative neuromonitor market.
Ø Insufficiency of skilled healthcare professional is one of the restraining factor of the intraoperative neuromonitor market.
]]>Market Insights
Cable cleat is a cable management product used to support and hold cables installed on trays/ladders or without conduit systems. These are useful in ensuring long life of cables as they reduce damage caused to the cables due to their own weight. Cable cleats have been useful in applications having heavy cables, power lines and transportation infrastructure.
The complete report is available at http://www.credenceresearch.com/report/cable-cleats-market
The market for cable cleats worldwide has received the necessary impetus from revival of the construction industry post economic recession. Additionally, the market has been witnessing impressive growth since the introduction of cable cleats of standard EN 50368 in 2003. Another major factor driving market growth is the advantages offered by cable cleats for effective cable management. Holding and maintaining the cable position even in the most critical conditions such as short circuits are easily handled by cable cleats. With the consistently growing efforts in innovating cleat designs, the market growth is estimated to remain strong throughout the forecast period.
The cable cleat providers across the world focus majorly on providing cable management solutions specific to different applications. This has significantly impacted the cable cleats industry in a positive manner. Manufacturers are now inclined towards designing cable cleats that can be used for specific applications such as high power cables, railway power cables, commercial buildings and several others. Cable cleat manufacturer emphasizes on expanding their product portfolio that can cater to varying requirements. These may include physical strength, various levels of short circuits, area of installation and several others. The trend is primarily governed by the consistently increasing competition in the overall cable management systems market worldwide.
Request Sample: http://www.credenceresearch.com/sample-request/58674
Competitive Insights:
The market for cable cleats is fairly unorganized and is characterized by a large number of local as well as international cable cleat manufacturers. Big players face tough competition from local players in terms of price and availability. Companies have been engaged in coming up with new and improved product designs and aim towards expanding their sales and distribution network. The use of more stable materials is one of the prime focus of cable cleats manufacturers. Major players in the market include Ellis Patents Ltd., Remora Electrical Limited, BICON, Eland Cables Limited, CMP Products Limited, Oglaend System Group, Nantong Naco Fluid Equipment Co. Ltd., IPD Group Limited, TransDelta International Industries L.L.C and Novoflex Marketing Pvt. Ltd.
Key Trends:
– Providing application specific solutions for cable management
– Distribution network expansion and acquisitions
– Consistently growing demand for cable cleats from the energy sector
]]>According to the latest report published by Credence Research, Inc. “Scar Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017-2025,” the global scar treatment market was valued at US$ 15.3 Bn in 2016, and is expected to reach US$ 35.0 Bn by 2025, expanding at a CAGR of 9.5% from 2017 to 2025.
Market Insights
Formation of scar is a typical reaction following any damage or surgery; it is the way the body mends harmed structures. Scar tissue may include just the shallow skin, or it might include the more profound tissues underneath the skin, including nerves and ligaments. The treatment of scar varies accordingly the type and depth of any scar. As per the data obtained from The American Board of Plastic Surgery, in 2016 181,000 procedures were performed only in U.S. which was increased by 1% from 2015.
Browse the full report Scar Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at http://www.credenceresearch.com/report/scar-treatment-market
Increasing incidences of skin disorder due to environmental pollution, radiation is the major driver of the scar treatment market. According to some research study, acne is evaluated to influence around 9.4% of the worldwide population, making it the eighth most common disease around the world. This rising trend of acne due to hormonal imbalance, inappropriate food-habits, and excessive stress positively influence scar treatment market to grow. The increasing adoption of technologically advanced procedures and products, healthcare expenditure for R&D to manufacture newer and innovative products, government approval on medical products, on rising awareness in public to improve physical appearance boost up the growth of scar treatment market. However, the expensive treatment procedures and side effects caused by few treatment procedures are few major challenges associated with the scar treatment market.
The scar treatment market is segmented on the basis of type of scars such as hypertrophic scars, keloid scars, atrophic scars and contractures. Among all the scar types, the atrophic scar is expected to dominate the scar treatment market due to increasing prevalence of acne. On the basis of treatment type the scar treatment market is segmented as surgical treatment, laser treatment, cosmetic treatment, injectable treatment and topical medication. The topical medication holds the major market share whereas laser treatment market is growing and anticipated to face significant growth in forecast period driven by its higher adoption rate and effective treatment procedures.
Based on the end-user types, the scar treatment market can be categorized into hospital, private clinics, drug store or retails store and e-commerce. Hospital segment although dominates the scar treatment market, but private clinic is anticipated to witness significant growth due to rising adoption rate of cosmetic procedure and laser treatment. The e-commerce and retail drug store will also face exponential growth due to high discounts and easy availability.
Geographically, in the year 2016, North America held the major share of scar treatment market followed by Europe. Increasing consciousness about public appearance, adoption of innovative products, increasing expenditure of healthcare to manufacture newer products, rising skin problems drive the market. On the other side, the Asia-Pacific region is assumed to face lucrative growth due to developing healthcare infrastructure and increasing public awareness about health. Asia-Pacific, being the polluted region, there is sharp growth in number of people affected by skin disorders which in turn driving the growth of scar treatment market.
Market Competition Assessment:
The scar treatment market comprises of numerous companies having their products marketed. However, most of the companies are located in the North America and others developed regions. The companies have untapped opportunities in the developing regions of Asia Pacific and Latin America. Companies are coming up with various products in the developed nations due to high acceptance and accessibilities of these products. The companies include Smith & Nephew plc., Lumenis, Sonoma Pharmaceuticals, Inc., Scarheal Inc., CCA Industries, Inc., Cynosure, Inc., Syneron Medical Ltd., Mölnlycke Health Care AB, Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Quantum Health, Hologic Inc. and others.
Request Sample: http://www.credenceresearch.com/sample-request/58671
Key Market Movements:
Ø The increasing incidence of skin problem, growing number of surgical procedures, rising adoption of technologically advanced procedures and products, growing healthcare expenditure for R&D to manufacture newer and innovative products, government approval on medical products, rising awareness in public to improve physical appearance are few major drivers of scar treatment market.
Ø High cost of treatment and adverse effects caused by scar treatment procedures pose some challenges on the growth of scar treatment market.
Market Insights
Hypercholesterolemia also known as high cholesterol, is the presence of excess levels of cholesterol in the body that increases a risk of developing heart attack, and stroke. Changes in lifestyle pattern such as the adoption of a sedentary form, increasing rate alcohol consumption and change in dietary pattern are driving the growth of hypercholesterolemia drugs market. For the purpose of the study hypercholesterolemia drugs market is segmented on the basis of drug class such as HMG-CoA reductase inhibitors/ statins, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, others drugs. It is studied that, currently HMG-CoA reductase inhibitors/ statins held largest market share because statins are commonly prescribed drug class due to their safety and effectiveness in lowering cholesterol.
Request Sample: http://www.credenceresearch.com/sample-request/58670
Browse the full report Hypercholesterolemia Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/hypercholesterolemia-drugs-market
In the base year 2016, North America dominated the global hypercholesterolemia drugs market due to the large number of target population, rise in geriatric population, increase in number of obese population with increase in risk of cardiovascular disease are prime contributors in North America. On the other hand, Asia Pacific will grow significantly during forecast period due to changing lifestyle and growing healthcare awareness that would assist the growth of hypercholesterolemia drugs market.
Market Competition Assessment:
The hypercholesterolemia drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbVie Inc., Aegerion Pharmaceuticals, Amgen Inc., AstraZeneca, Eli Lilly and Company, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Shore Therapeutics, Inc., Teva Pharmaceuticals and other.
Key Market Movements:
Browse the full report Hypercholesterolemia Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/hypercholesterolemia-drugs-market
]]>Market Insights
The global pyrogen testing market is undergoing significant growth due to rapid proliferation of biotechnology, pharmaceuticals and medical devices industries. Increasing pace of commercialization of biotherapeutics, pharmaceuticals and medical devices has resulted in increased demand for pyrogen testing in manufacturing processes. Growth in number of biotechnology and pharmaceutical companies and increasing R&D initiatives to launch novel drugs and devices also significantly contribute to growth of this market. On the other hand, ethical restrains on animal testing and thus the usage of rabbits for pyrogen testing will hold back the market growth. Emergence of pharmaceutical, biotechnology and medical companies, and growing CRO and CMO activities in emerging economies will open lucrative opportunities for pyrogen testing solutions providers.
Browse the full report Pyrogen Testing Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at http://www.credenceresearch.com/report/pyrogen-testing-market
Based on test types, the global pyrogen testing market is classified into rabbit pyrogen test (RPT), limulus amoebocyte lysate (LAL) assay (chromogenic tests, turbidimetric tests and gel clot tests) and monocyte activation test (MAT) (In-vitro test). LAL tests is expected to be the fastest progressing segment during the forecast period. Rising demand for animal-free testing along with proven accuracy and efficiency of in-vitro testing. However, due to being in practice for a longer duration, rabbit pyrogen test is the largest revenue generating segment in the global pyrogen testing market. However, increasing pressure with regards to adoption of animal-free testing methods may restrain the market growth.
Based on the product types, the global pyrogen testing market is classified into reagents and kits, instruments and systems and services. Among these, the reagents and kits i.e. the consumables segment is the largest segment in 2016 and will continue to retain its dominance through the forecast period. Additionally, the instruments segment is anticipated to undergo the fastest growth rate during the forecast period due to rapid replacement of older systems attributed to technological innovation.
Pharmaceutical and biotech manufacturing, medical device manufacturing and others (cosmetics and personal care products, etc.) are the major categories of applications of pyrogen testing. Pharmaceuticals and biotech manufacturing is the largest application of pyrogen testing due to high need of reagents and kits, and novel instrumentation in this sector. Perpetual technological innovation due to the growing need for evolved and safer medical devices has urged the need for pyrogen testing methods in this field.
Geographically, North America is the dominant regional market for pyrogen testing. Extensive domicile of pharmaceutical and biotech manufacturers chiefly contribute to the largest revenue share of North America on the global front. Existence of evolved healthcare and biotechnology research infrastructure and extensive urge to introduce novel drugs and medical devices also drive the North America pyrogen testing market. Furthermore, Asia Pacific will witness the fastest growth during the forecast period 2017-2025. Burgeoning number of biotechnology companies and increasing CRO activities in the region are the chief drivers of Asia Pacific market.
Browse the full report Pyrogen Testing Market – Growth, Future Prospects and Competitive Analysis, 2017–2025 report at http://www.credenceresearch.com/report/pyrogen-testing-market
]]>Market Insights:
According to Provista Diagnostics, there are six types of biomarkers in cancer research such as risk assessment, screening/detection, diagnosis, prognosis, prediction and monitoring. In case of risk assessment biomarkers identify factors to access disease susceptibility, screening biomarkers indicate the early presence of disease, and predicting biomarkers predict efficacy or response to several treatments.
Browse the full report Cancer Biomarkers Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 – 2025 report at http://www.credenceresearch.com/report/cancer-biomarkers-market
In recent years, remarkable advances have taken place in understanding the molecular mechanism of cancer progression which has transformed the way people can observe the process of malignant transformation. Moreover, market experts also feel that this knowledge should be translate to provide better treatments for cancer patients. This development has successfully enticed the interest towards the development of targeted therapies for cancer and personalized medicine.
The overall market segmentation of cancer biomarkers market comprises by type, cancer type, profiling technologies type, and application type. In year 2016, proteomic biomarkers dominated the market by type due to exceptional market potential of protein biomarkers in diagnostics, prognostics, cancer detection and other clinical & therapeutic applications. In addition, increasing focus of pharmaceutical & biotechnology companies in research and development of protein biomarkers is expected to fuel the overall market growth.
In year 2016, breast cancer dominated the cancer biomarkers market by cancer type due to rising prevalence of disease, high awareness associated with early diagnosis, increasing public awareness with assistance of government and non-government organizations, and rising research and development activities in the field of breast cancer diagnosis. During the forecast period 2017 – 2025, lung cancer was observed as the fastest growing segment due to key driving factors such as rising prevalence of lung cancer due to increase in air pollution and frequent smoking observed in young generation.
Request Sample: http://www.credenceresearch.com/sample-request/58676
In case of profiling technologies omics technologies accounted for the largest share of the cancer biomarkers market and also the fastest growing segment due to key driving factors such as increased adoption of advanced high throughput technologies in biomarker discovery and development and rising application of omics-based tests for cancer diagnosis and drug development process. In addition, incessant developments in high-throughput omics technologies are also backing the growth of this market, by rising the space of prospective biomarkers in cancer research.
In year 2016, applications segment was dominated by diagnostics due to key driving factors such as increasing awareness amongst patients about the importance of early diagnosis of cancer and diagnostic biomarkers enable doctors to decide effective treatment alternatives.
North America dominated the cancer biomarkers market in year 2016 due to key driving factors such as increasing adoption of innovative technology, headquarters of key pharmaceutical companies are based in North America, established R&D infrastructure pertaining to the development of novel diagnostic products, and increased demand for specific & early diagnostics. Asia Pacific region was observed as the fastest growing segment due to increasing prevalence of cancer, beneficial environment for clinical trials, and increasing government support for drug development programs is anticipated to witness lucrative CAGR.
Market Competition Assessment:
The cancer biomarkers market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure Inc. Qiagen N.V., Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies Inc., Merck & Co. Inc., Hologic, Inc., and Becton Dickinson and Company among others.
Key Market Movements:
Market Insights
Hereditary angioedema is a rare autosomal dominant disorder and has disease epidemiology of one individual per 10,000 – 50,000 without major sex or ethnic differences. Hereditary angioedema has resulted in tremendous humanistic burden on patients in terms of poor physical and mental health causing a major setback on education, career, work productivity and socioeconomic impediment. Introduction of disease specific treatment drugs in the past decade has improved patients’ quality of life and reduced the cost related to hospitalization.
Request Sample: http://www.credenceresearch.com/sample-request/58675
Browse the full report Hereditary Angioedema Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/hereditary-angioedema-market
In 2016, C1 esterase inhibitors segment dominated the market due to the recent approval of novel drugs: Berinert and Haegarda. Additionally, technological advancement in drug delivery (for e.g. Haegarda is the only medication available as a subcutaneous treatment option). Kallikrein inhibitors is expected to be the fastest growing segment throughout the forecast period 2017-2025, majorly due to increasing incidences in patients with severe angioedema anaphylactic shock and promising product pipeline, touted to offer better results than the existing treatment options. The drug in Phase III DX 2930 has received breakthrough therapy designation and orphan drug designation by the USFDA. Phase II drug BCX-7353 is an oral preparation to counteract the severe swelling attacks in the intestinal and airway tract.
In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of hereditary angioedema, increasing expenditure by the pharmaceutical giants in the research and development to counteract hereditary angioedema symptoms and existence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as increasing frequency of symptoms in patients suffering with hereditary angioedema requiring immediate medical intervention, increasing disposable incomes in these regions and supportive regulatory environment for hereditary angioedema drugs.
Key Market Movements:
Market Insights
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. According to American Cancer Society study in U.S. around 63,990 adults (40,610 men and 23,380 women) new cases of kidney cancer will be diagnosed.
Request Sample: http://www.credenceresearch.com/sample-request/58677
Browse the full report Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/kidney-cancer-renal-cell-carcinoma-rcc-drugs-market
The average age of diagnosis is 64 and is rarely found in people under 45. It is estimated that 65% of people are diagnosed when the cancer is only located in the kidney and the 5-year survival rate is 93% in this group. The incidence of renal cell cancer is observed highest in Northern America and Europe. Almost 59%of kidney cancer cases is observed in developed countries. Thus, rising incidence of kidney cancer and entry of novel drug treatment are the key factors contributing to the growth of kidney cancer drug market.
The global kidney cancer drugs market is segmented by drugs type into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). Sutent dominates the global kidney cancer/renal cell carcinoma drugs market.
As of the current market scenario, North America dominates the global kidney cancer drugs market followed by the Europe. Rise in incidence of renal cancer, increasing geriatric population and novel drug treatment are key drivers for the growth of kidney cancer drug market in North America. Asia Pacific is the fastest growing regional market for kidney cancer drugs with highest CAGR in the forecast period. With improvement in diagnostic technology, rise in aged population and low cost production of drugs are some of the key factors contributing to the growth of Asia Pacific region.
Market Competition Assessment:
Key players in the global kidney cancer drugs market are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., Glaxosmithkline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.
Key Market Movements:
Market Insights
Cement demand is expected to grow at a rate of 7.3% between 2017 and 2025; factors such as increasing urbanization and industrialization are currently fuelling the growth of the global cement market. In terms of value, Asia-Pacific dominates the cement market accounted for over 70% share of the global cement market in 2016. China is the largest in terms of value and volume, accounted for over 65% of Asia-Pacific cement market in 2016. China is followed by India, which is the fastest growing market and holds the second position in terms of volume consumption.
Request Sample: http://www.credenceresearch.com/sample-request/58688
Browse the full Cement Market- Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/cement-market
The cement demand relies on construction and building activities, thus infrastructure development. Cement is the major ingredient for concrete and mortar which are used in the construction industry. Hence, rise in construction or building activities worldwide will largely spur the market. Also factors that could influence the rise in the worldwide market include escalating number of nuclear families, rising need for accommodation, development in technology and commercial establishments, and escalating disposable income.
Cement industry is highly fragmented with existence of large, medium, and small manufacturers across the world. Lafarge is the largest manufacturer and holds the major market share in the cement market, globally. Producers are also involved in development in manufacturing of colored cement to cater the changing demand of end-use customers. Anhui Conch Cement Co., Ltd., CEMEX S.A.B. de C.V., China National Materials Co., Ltd., Eurocement Group, UltraTech, Taiheiyo Cement Corporation, Heidelberg Cement AG, LafargeHolcim Ltd., China Tianrui Group Cement Company Limited, China Shanshui Cement Group Ltd., Buzzi Unicem S.p.A., CIMPOR – CIMENTOS DE PORTUGAL, SGPS, S.A., Siam Cement Group Public Company Limited, Jaypee Group, Vicat SA, Dangote Group, Fars & Khuzestan Cement Co., OYAK (Ordu Yardimlasma Kurumu) Cimento A.S., Cementir Holding S.p.A., Ramco Cements Ltd., Mitsubishi Materials Corporation, TPI Polene Public Company Ltd., Limak Holding A.S., Saudi Cement. ITD and JK Cement Ltd. are the few key manufacturers in cement market.
Key Trends:
Latest Reports:
http://www.credenceresearch.com/report/moulded-fibre-pulp-packaging-market
http://www.credenceresearch.com/report/pressure-relief-devices-market
]]>Market Insights
Kaposi sarcoma has an incidence rate of 0.02-0.06 %, it is widely prevalent in middle aged Afro-American men, East-European and Mediterranean region men of Jewish origin (Ashkenazi). Kaposi sarcoma has overwhelming male predominance. Serological assays for the detection of Kaposi sarcoma are limited and has often resulted in the production of conflicted data with different methodologies. Polymerase chain reaction, insitu hybridization, and immunohistochemistry reveal the KSHV proteins expressed in the human tissue.
Request Sample: http://www.credenceresearch.com/sample-request/58687
Browse the full report Kaposi sarcoma Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/kaposi-sarcoma-market
In 2016, HAART (highly active antiretroviral therapy) segment dominated the market due to rising prevalence of AIDS, as patients suffering with HIV infection are 20,000 times prone to develop Kaposi sarcoma and the proactive government initiative such as United States Presidents Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS. Chemotherapy will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as technological advancement in the drug formulation for e.g. paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS surpassing the drug biotransformation which is toxic to liver cells. Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes acid sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues.
In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of Kaposi sarcoma, presence of pharmaceutical giants primarily focusing on Kaposi sarcoma treatment and presence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to increasing disposable incomes in these regions and supportive regulatory environment for Kaposi sarcoma drugs.
Key Market Movements:
Latest Reports:
http://www.credenceresearch.com/report/moulded-fibre-pulp-packaging-market
http://www.credenceresearch.com/report/pressure-relief-devices-market
]]>Watch video on YouTube here: Google Maps Q&A
via S&S Pro Channel
Watch video on YouTube here: Google Maps Q&A
via S&S Pro Channel
Watch video on YouTube here: Online Marketer Denver
via S&S Pro Channel
Watch video on YouTube here: Online Marketer Denver
via S&S Pro Channel
Watch video on YouTube here: Online Marketer Denver
via S&S Pro Channel
Watch video on YouTube here: Online Marketer Denver
via S&S Pro Channel
Watch video on YouTube here: http://youtu.be/__meU9RsJew
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/__meU9RsJew
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/m6_LrH42mL0
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/m6_LrH42mL0
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/BDwC5qQlNf0
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/BDwC5qQlNf0
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/fb9Ot0SbDtc
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/fb9Ot0SbDtc
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/kTXdmAHlilk
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/kTXdmAHlilk
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/rpFbdDn7Z4E
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/rpFbdDn7Z4E
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/-Zx1PgHYwSA
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/-Zx1PgHYwSA
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/fH-CUVwz8w4
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/fH-CUVwz8w4
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/K8eDagYps70
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/K8eDagYps70
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/kZ1geCI4OLs
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/kZ1geCI4OLs
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/i55TgmcjDbU
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/i55TgmcjDbU
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/k6wmFQw7iBk
via CHANNEL-URL-HERE
Watch video on YouTube here: http://youtu.be/k6wmFQw7iBk
via CHANNEL-URL-HERE